Neil Dixon received a MChem (Hons) 1st class from the University of Leeds (UK) in 2000 and then undertook in his PhD in Bioorganic Chemistry also at Leeds on “Probing the inhibition of the vacuolar (H⁺)-ATPase: targeting osteoporosis” (2004), using small molecule probes and a combination biophysical of biochemical techniques to elucidate ligand-membrane proteins interactions. After an extended period travel in Latin America he then pursued post-doctoral research in Chemical Biology at the University of Manchester (UK) on the topic re-engineering the molecular recognition properties of regulatory RNA motif (riboswitches), using rational design, high-throughput screening, directed evolution, in combination with biochemical and biophysical characterization (2006-2010).
In 2010 he was independently awarded the BBSRC Enterprise to explore the commercial exploitation of the RiboTite technology based on his post-doc research, following this he additionally secured BBSRC Follow on Funding 2012-13, as Researcher Co-Investigator, to further validated the technology and support a patent application. In 2013 in was awarded the prestigious BBSRC David Phillips Fellowship and established is independent research laboratory. His group currently comprising of 2 post doctoral scientist, 4 PhD students and 1 Research Technician is supported from BBSRC, EPSRC, Innovate UK, Wellcome Trust, Brazilian and Indonesian Governments.